20:22 , Dec 16, 2016 |  BC Week In Review  |  Financial News

amcure completes venture financing

amcure raised €6 million ($6.3 million) in a series B round led by LBBW Venutre Captial. KfW, MBG Mittelstaendische Beteiligungsgesellschaft Baden-Wuerttemberg, S-Kap Unternehmensbeteiligungs, Karlsruhe Institute of Technology (KIT) and private investors also participated. amcure GmbH...
23:07 , Nov 2, 2016 |  BC Week In Review  |  Clinical News

AMC303: Ph I/Ib started

amcure began an open-label, dose-escalation, dose-expansion, European Phase I/Ib trial to evaluate AMC303 in up to 50 patients. amcure GmbH , Eggenstein-Leopoldshafen, Germany  Product: AMC303   Business: Cancer  Molecular target: Splice variant v6 of CD44...
07:00 , Jul 28, 2014 |  BioCentury  |  Emerging Company Profile

amcure: Reimagining angiogenesis

amcure GmbH is developing peptide-based inhibitors of CD44v6 , a tumor-specific co-receptor of tyrosine kinases including VEGFR-2 and c-Met . The approach could allow for higher dosing with fewer side effects than direct-acting tyrosine kinase...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Financial News

amcure completes venture financing

amcure GmbH , Eggenstein-Leopoldshafen, Germany   Business: Cancer   Date completed: 2014-07-15   Type: Venture financing   Raised: EUR5 million ($6.8 million)   Investors: LBBW Venture Capital; KfW; MBG Baden-Wuerttemberg; S-Kap Beteiligungen Pforzheim; BioM; private...